Krystal Biotech’s (KRYS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research note released on Tuesday morning, Benzinga reports. They currently have a $221.00 target price on the stock. HC Wainwright also issued estimates for Krystal Biotech’s FY2026 earnings at $7.02 EPS.

Other equities analysts have also recently issued reports about the stock. Evercore ISI raised their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research note on Monday, August 12th. Citigroup reaffirmed a “neutral” rating and issued a $204.00 target price (up previously from $195.00) on shares of Krystal Biotech in a research report on Tuesday, August 6th. Chardan Capital boosted their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Finally, Stifel Nicolaus boosted their price target on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $197.00.

Krystal Biotech Stock Up 2.1 %

Shares of NASDAQ:KRYS opened at $174.41 on Tuesday. The firm has a market cap of $5.01 billion, a price-to-earnings ratio of 98.54 and a beta of 0.82. Krystal Biotech has a 12 month low of $93.95 and a 12 month high of $219.34. The company’s fifty day simple moving average is $181.81 and its 200 day simple moving average is $180.23.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.07. The firm had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The company’s revenue for the quarter was up 879.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.67) EPS. Research analysts expect that Krystal Biotech will post 2.88 earnings per share for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the transaction, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 14.10% of the company’s stock.

Institutional Trading of Krystal Biotech

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Jamison Private Wealth Management Inc. acquired a new stake in Krystal Biotech during the second quarter worth approximately $28,000. GAMMA Investing LLC lifted its position in Krystal Biotech by 160.3% during the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after purchasing an additional 93 shares during the period. Key Financial Inc bought a new stake in Krystal Biotech during the second quarter worth about $28,000. Blue Trust Inc. grew its stake in Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after buying an additional 163 shares in the last quarter. Finally, Values First Advisors Inc. bought a new position in Krystal Biotech in the 3rd quarter valued at about $53,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).